Table 3.

Analyses of risk factors for HCC early recurrence

		Recurrence		Univariate analysis			Multivariate analysis
		No	Yes	HR (95% CI)	χ 2	P*	HR (95% CI)	χ 2	P
Age (years)	≤ 50	8	10	0.586 (0.266–1.291)	1.759	0.185	–	–	–
	> 50	28	16
Gender	Male	33	25	0.501 (0.068–3.695)	0.460	0.497	–	–	–
	Female	3	1
Tumor size (cm)	≤ 5 cm	18	7	2.393 (1.003–5.710)	3.867	0.049	NS
	> 5 cm	18	19
Cirrhosis	No	25	17	1.203 (0.536–2.700)	0.201	0.654	–	–	–
	Yes	11	9
Portal vein Tumor thrombus	No	34	17	4.275 (1.852–9.869)	11.585	0.001	2.905 (1.159–7.280)	5.179	0.023
	Yes	2	9
Child-Pugh class	A	32	20	1.842 (0.737–4.606)	1.708	0.191	–	–	–
	B	4	6
HBsAg	Negative	6	5	0.944 (0.356–2.504)	0.014	0.907	–	–	–
	Positive	30	21
AFP (μg/L)	≤ 400	28	15	2.181 (0.996–4.776)	3.798	0.051	NS
	> 400	8	11
CEA (μg/L)	≤ 5	32	22	1.311 (0.451–3.808)	0.247	0.619	–	–	–
	> 5	4	4
CA199 (kU/L)	≤ 34	27	16	1.699 (0.770–3.751)	1.720	0.190	–	–	–
	> 34	9	10
Total CTCs	Negative	21	6	2.950 (1.184–7.349)	5.393	0.020	NS
	Positive	15	20
Mixed CTCs	Negative	25	9	2.935 (1.306–6.594)	6.797	0.009	NS
	Positive	11	17
Mesenchymal CTCs	Negative	29	8	4.740 (2.041–11.010)	13.099	0.000	3.453 (1.393–8.559)	7.157	0.007
	Positive	7	18
Edmondson stage	I–II III–IV	35 1	23 3	0.343 (0.103–1.148)	3.011	0.083	NS
BCLC stage	0 + A	14	9	1.362 (0.606–3.060)	0.560	0.454	–	–	–
	B + C	22	17
ALP (U/L)	≤ 160	32	19	2.178 (0.906–5.236)	3.025	0.082	NS
	> 160	4	7
ALT (U/L)	≤ 75	27	22	0.656 (0.225–1.907)	0.601	0.438	–	–	–
	> 75	9	4

*P < 0.10 will be further multivariate analysis

NS non-significance, AFP alpha-fetoprotein, HBsAg hepatitis B surface antigen, CEA carcinoembryonic antigen, CA199 carbohydrate antigen 199, BCLC stage Barcelona Clinic Liver Cancer stage, ALP alkaline phosphatase, ALT, alanine aminotransferase